Claims for Patent: 9,801,898
✉ Email this page to a colleague
Summary for Patent: 9,801,898
Title: | Glutamate dehydrogenase 1 inhibitors and methods of treating cancer |
Abstract: | This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof. In certain embodiments, the inhibitor has Formula I: ##STR00001## prodrugs, derivatives, or salts thereof wherein the substituents are reported herein. In certain embodiments, the inhibitor is purpurin, derivative, or salt thereof. In certain embodiments, the inhibitor is 2-allyl-1-hydroxyanthracene-9,10-dione, prodrugs, derivatives, or salts thereof. |
Inventor(s): | Kang; Sumin (Decatur, GA), Chen; Jing (Atlanta, GA), Jin; Lingtao (Atlanta, GA) |
Assignee: | Emory University (Atlanta, unknown) |
Application Number: | 15/017,095 |
Patent Claims: | 1. A method of treating cancer comprising administering an effective amount of 2-allyl-1-hydroxyanthracene-9,10-dione or salts thereof to a subject in need thereof.
2. The method of claim 1 wherein the inhibitor is administered in combination with a second chemotherapeutic agent. 3. The method of claim 2, wherein the second chemotherapeutic agent is gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vincristine, vinblastine, vindesine, vinorelbine taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin bortezomib anegrilide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, bevacizumab, combretastatin, thalidomide, and/or lenalidomide or combinations thereof. 4. The method of claim 1, wherein the cancer is selected from the group consisting of leukemia, cervical, ovarian, colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate, and renal cancer. |
Details for Patent 9,801,898
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-02-06 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-02-06 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2035-02-06 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2035-02-06 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2035-02-06 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2035-02-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.